Addiction

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

Retrieved on: 
Monday, January 8, 2024

NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer's, Parkinson's, and even drug addiction, plus there are strong indications of therapeutic efficacy in heart disease and chronic kidney disease, as well as a wide range of other conditions, including weight loss. The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile). By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. With several key studies on the near-term horizon, Lexaria has positioned itself in the midst of these market opportunities alongside others changing the landscape, such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Novo Nordisk (NYSE: NVO).

Key Points: 
  • GLP-1 agonists are the hottest drugs in healthcare today, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Similarly, product sales for obesity drugs are forecast to reach $100 billion within a decade, and the most promising drugs at the head of the pack are GLP-1 agonists.
  • Novo Nordisk (NYSE: NVO) , the owner of Ozempic(R), Rybelsus(R), Victoza(R) and Wegovy(R), is a world leader in diabetes and GLP-1 drugs.
  • Companies that enhance efficacy and expand usage could prove to be the biggest winners in the progression of GLP-1 drugs.

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

Retrieved on: 
Monday, January 8, 2024

NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer's, Parkinson's, and even drug addiction, plus there are strong indications of therapeutic efficacy in heart disease and chronic kidney disease, as well as a wide range of other conditions, including weight loss. The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile). By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. With several key studies on the near-term horizon, Lexaria has positioned itself in the midst of these market opportunities alongside others changing the landscape, such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Novo Nordisk (NYSE: NVO).

Key Points: 
  • GLP-1 agonists are the hottest drugs in healthcare today, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Similarly, product sales for obesity drugs are forecast to reach $100 billion within a decade, and the most promising drugs at the head of the pack are GLP-1 agonists.
  • Novo Nordisk (NYSE: NVO) , the owner of Ozempic(R), Rybelsus(R), Victoza(R) and Wegovy(R), is a world leader in diabetes and GLP-1 drugs.
  • Companies that enhance efficacy and expand usage could prove to be the biggest winners in the progression of GLP-1 drugs.

Priscilla: a bold feminist retelling of Elvis' dark fairytale marriage

Retrieved on: 
Friday, January 5, 2024

Over the course of the relationship, we see Priscilla grow from girlhood to womanhood.

Key Points: 
  • Over the course of the relationship, we see Priscilla grow from girlhood to womanhood.
  • On the surface, the story of Elvis and his wife Priscilla has all the qualities of a modern fairy tale.
  • She becomes queen to the “King of Rock and Roll” and they live happily ever after in their Memphis palace.
  • Coppola’s biopic in fact exposes the dark heart of this fairytale.

The lens of #MeToo

  • The audience watches as Priscilla matures under the shadow of Elvis’ controlling influence.
  • The #MeToo feminist landscape has shaped the story Coppola tells about Elvis and Priscilla.
  • The Twitter hashtag #MeToo was popularised in 2017 to expose the widespread abuse of women in Hollywood by the film producer Harvey Weinstein.
  • Priscilla is the latest in a cycle of post-#MeToo feminist retellings that offer a more sympathetic take on women in the spotlight.

Power and abuse

  • The film makes a comment about how powerful men are able to abuse their positions.
  • Coppola’s script emphasises the unequal power dynamic between Elvis and Priscilla, including the age difference.
  • The film shows how a toxic blend of fame, wealth and status draws people into Elvis’ orbit and, in turn, how his star power allows him to behave in ways that are rarely challenged by those around him.


Looking for something good? Cut through the noise with a carefully curated selection of the latest releases, live events and exhibitions, straight to your inbox every fortnight, on Fridays. Sign up here.
Harriet Fletcher does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Personality predicting relapse: A facet analysis of the NEO PI‐R - A recent study published in The American Journal on Addictions

Retrieved on: 
Friday, January 5, 2024

This study provides an in-depth analysis of the individual facets of the NEO PI-R (personality assessment test) domains and their association with substance use disorders.

Key Points: 
  • This study provides an in-depth analysis of the individual facets of the NEO PI-R (personality assessment test) domains and their association with substance use disorders.
  • The research provides insight into the nuances of potential relapse and how personality traits may provide valuable information to treatment providers and individuals alike.
  • "Making a continued effort to study outcomes is essential for continued quality improvement for any addiction program.
  • Having consistent predictive measures such as personality inventories can inform treatment planning and interventions that can assist at improving outcomes.

Anonymous Health Launches Innovative Addiction Care Services in Alaska

Retrieved on: 
Wednesday, January 3, 2024

ANCHORAGE, Alaska, Jan. 3, 2024 /PRNewswire/ -- Anonymous Health, a pioneer in outpatient teletherapy services, is proud to announce its launch in Alaska.

Key Points: 
  • ANCHORAGE, Alaska, Jan. 3, 2024 /PRNewswire/ -- Anonymous Health, a pioneer in outpatient teletherapy services, is proud to announce its launch in Alaska.
  • This marks a significant step in addressing the complex challenges of addiction care across the state.
  • "We are excited to help address long-standing capacity and access challenges of addiction care in Alaska," said Medical Director, Dr. Palani Chidambaram.
  • Personalized Care and Advanced Technology: Anonymous Health's Approach
    Patients at Anonymous Health receive near-immediate attention from a dedicated Concierge Care Manager.

Psychiatry and Neuroscience Expert Dr. Joel Raskin Joins ArrivoBio as Chief Medical Advisor

Retrieved on: 
Wednesday, January 3, 2024

Arrivo BioVentures proudly announces the appointment of Dr. Joel Raskin as its Chief Medical Advisor (CMA).

Key Points: 
  • Arrivo BioVentures proudly announces the appointment of Dr. Joel Raskin as its Chief Medical Advisor (CMA).
  • View the full release here: https://www.businesswire.com/news/home/20240103994981/en/
    Dr. Joel Raskin joins ArrivoBio as Chief Medical Advisor.
  • (Photo: Business Wire)
    “We are honored to welcome Dr. Joel Raskin to our team as we continue to advance our novel therapies SP-624 and RABI-767,” said Steve Butts, CEO of Arrivo.
  • Over the course of his career, Dr. Raskin has published nearly 100 scientific articles.

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series

Retrieved on: 
Wednesday, January 3, 2024

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided an update on data underpinning the selection of EB-003 as its lead drug candidate from the Company’s next-generation EVM301 Series.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided an update on data underpinning the selection of EB-003 as its lead drug candidate from the Company’s next-generation EVM301 Series.
  • 5-HT2A is the key receptor correlated to the neuroplastogenic activity of this emerging class of novel drugs.
  • 5-HT1A is a known important therapeutic target because other, already-approved medications for neuropsychiatric indications are known to bind this receptor.
  • HTR is a rodent behavioral model used to predict whether a molecule is likely to produce hallucinogenic effects in humans.

Inspiring True Stories about the Journey from Felon to Faithful

Retrieved on: 
Wednesday, January 3, 2024

PHOENIX, Jan. 3, 2024 /PRNewswire-PRWeb/ -- Dedicating more than 20 years to ministry, Norman O. Christianson, Scribe has opened his doors to women who have endured hardship, helping them to overcome their past. He shares some of their stories in "The Fourth Watch: A Woman's Journey."

Key Points: 
  • He shares some of their stories in "The Fourth Watch: A Woman's Journey."
  • Christianson shares how he and his wife, Elizabeth, have spent the 20 years ministering to women who have suffered from addiction, abuse, or have been incarcerated.
  • All the stories shared in "The Fourth Watch" are true, shared with Christianson by the women who experienced them.
  • In addition to the stories of the women he has helped, Christianson also shares some stories of his own.

Syra Health Wraps Up a Successful 2023, including New Contracts, Contract Extensions, and the introduction of new Healthcare Innovations

Retrieved on: 
Tuesday, January 2, 2024

Within its Behavioral and Mental Health Business Unit, Syra Health:

Key Points: 
  • Within its Behavioral and Mental Health Business Unit, Syra Health:
    Launched Syrenity, the Company's flagship mental and behavioral product, focused on preventing mental health crises.
  • Secured a five-year, $4.75 million contract with the District of Columbia's Department of Behavioral Health, to support vital mental health programs in communities.
  • Across its Digital Health Business Unit, Syra Health:
    Launched CarePlus, an easy-to-use, secure, and scalable electronic medical record (EMR) system for small and mid-sized healthcare organizations.
  • "2023 was a transformative year for Syra Health," said Dr. Deepika Vuppalanchi, CEO, Syra Health.

God Extends Forgiveness Regardless of Actions, Identities and Current Circumstances

Retrieved on: 
Tuesday, January 2, 2024

NEWPORT BEACH, Calif. , Jan. 2, 2024 /PRNewswire-PRWeb/ -- Author Fabrice Poigin aims to help readers looking for personal growth and a relationship with God in THE HUNGER WITHIN: A CHEF'S PROFOUND JOURNEY THROUGH HIS WORLD ($20.49, paperback, 9781662888656; $8.99, e-book, 9781662888663).

Key Points: 
  • Writing about one's inner struggles can be a cathartic process and a way to make sense of personal challenges.
  • Fabrice Poigin, a world travelled French Chef, penned this creatively written, thought-provoking book to help men of all ages savor the nourishing bread of life.
  • Poigin, who himself, has faced personal struggles with addiction, has sought assistance and knowledge in this area, leading to his own healing journey.
  • He now takes what he has experienced and provides readers with the ultimate reality that God stands ready to extend forgiveness to his followers, regardless of one's actions, identity, or current life circumstances.